DGAP-News: CerMed International Inc.: CerMed International Acquires Viridis Bioscience
(firmenpresse) - DGAP-News: CerMed International Inc. / Key word(s):
Acquisition/Mergers&Acquisitions
CerMed International Inc.: CerMed International Acquires Viridis
Bioscience
25.05.2011 / 09:10
---------------------------------------------------------------------
CONTACT
CerMed International
(831) 920 2275 (o)
info(at)cermedint.com
www.cermedint.com
CerMed International Acquires Viridis Bioscience
Monterey, CA - May 25, 2011 - CerMed International, Inc. based in Monterey,
CA announces the acquisition of Viridis Bioscience of Essex Junction, VT
along with existing licensing agreements related to the development of an
electrode-based point of care (POC) system for rapid detection of
infectious disease
Viridis's licensing agreement covers the adaptation of a non-optical,
high-density electrode array for POC detection of specific carbohydrates,
drugs, drug metabolites, lipids and proteins indicative of infectious
disease or specific medical conditions. Viridis' licensed platform provides
CerMed with a disposable, compact, portable microelectrode array with
improved sensitivity and specificity for protein-based detection relative
to lateral flow, or optical-based immunological platforms.
CerMed intends to apply the platform in low cost, highly sensitive POC
assays for detection of infectious agents and diseases related to women's
health, in particular reproductive health. CerMed will market the platform
as a means to rapidly screen women for cervical neoplasia, initially in
areas underserved by current medical practice. The majority of new cases of
cervical cancer resulting from infection with the human papillomavirus
(HPV) occur in underdeveloped countries, due primarily to a lack of
infrastructure, personnel, and the high costs associated with screening
women using PAP smears, the current industry standard. The portability,
improved sensitivity, and rapid function of the new platform will allow
CerMed to reach the areas of greatest need, improving the delivery of
health care to women worldwide at significantly reduced cost and time
compared with typical screening methods. CerMed's platform will be the
first of its kind to offer a rapid means to screen for both the presence of
HPV as well as the status of neoplasia, an advantage over both PAP smear
and nucleic acid based screening, providing improved marketing and delivery
options for healthcare.
About CerMed International
CerMed International, Inc. is an emerging global medical device company
that develops products and systems that help improve the health of women
worldwide. These lower cost products will aid in reducing the risk of
female reproductive diseases. They will enable women's health initiatives
to be brought to the underserved regions of the world and empower women to
personally take steps to reduce the risk of HIV and other STD's.
For information: http://www.cermedint.com
Contact: info(at)cermedint.com
Phone: 831-920-2275
End of Corporate News
---------------------------------------------------------------------
25.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
126078 25.05.2011
Datum: 25.05.2011 - 09:10 Uhr
Sprache: Deutsch
News-ID 34196
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: CerMed International Inc.: CerMed International Acquires Viridis Bioscience"
steht unter der journalistisch-redaktionellen Verantwortung von
CerMed International Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
